AMA and EMA issue guidelines to fast-track Bundibugyo virus vaccines

The African Medicines Agency and European Medicines Agency released joint guidance to accelerate clinical trials amid public health emergencies in the DRC, Uganda, Kenya and Nigeria.

The African Medicines Agency (AMA) and the European Medicines Agency (EMA) have issued joint guidelines to accelerate the development and clinical testing of vaccines against the Bundibugyo virus (BDBV). The virus causes a form of Ebola disease.

The guidance aims to fast-track clinical trials while maintaining scientific standards and protecting participants, particularly vulnerable groups. The initiative follows scientific consultations with the World Health Organization (WHO) on August 24, 2026.

The agencies released the position paper amid a public health emergency in the Democratic Republic of the Congo (DRC), with cases also reported in Uganda, Kenya and Nigeria. Regulators emphasized advancing potential vaccines through clinical trial phases without unnecessary delays while ensuring safety assessments.

Under the guidelines, vaccine developers using messenger RNA (mRNA) or certain viral-vector platforms may be exempted from repeating some toxicity studies if sufficient safety evidence exists. Existing safety data from similar technologies could support faster progression into early-stage human trials.

The agencies recommended conducting initial trials in Africa to facilitate larger studies among populations at risk. They also proposed evaluating effectiveness through Phase III ring vaccination trials involving people who have had close contact with confirmed Ebola patients.

The guidelines recommend prioritizing single-dose vaccines for easier administration during outbreaks. Studies involving children and pregnant women should begin once sufficient preliminary safety data are obtained from adult participants.

Key facts

  • The AMA and EMA issued joint guidelines to accelerate Bundibugyo virus vaccine development.
  • Cases of the virus have been reported in the DRC, Uganda, Kenya and Nigeria.
  • Developers using mRNA or viral-vector platforms may be exempted from some toxicity studies.

Three perspectives

Neutral

The African Medicines Agency and the European Medicines Agency have released joint guidelines to speed up Bundibugyo virus vaccine trials.

Positive

The initiative seeks to accelerate the availability of safe and effective vaccines through closer collaboration between African and European regulators.

Negative

The guidelines address a public health emergency with reported cases in the DRC, Uganda, Kenya and Nigeria.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

All sections

Edition